Literature DB >> 2845316

Human parvovirus infection in pregnancy.

J F Rodis1, T J Hovick, D L Quinn, S S Rosengren, P Tattersall.   

Abstract

During an outbreak of fifth disease in the Hartford, Connecticut area in the winter of 1986, nine pregnant women were exposed to the parvovirus. Five of these nine had serologic evidence of previous exposure and immunity; all five had uneventful pregnancies. Three of the four women who exhibited serologic evidence of recent exposure to the parvovirus had hydropic fetuses who died, one of whom was anencephalic. Histologic and DNA hybridization studies suggest parvovirus infection as a cause for nonimmune hydrops and fetal death. A review of the literature suggests that of 37 women who were exposed and infected by human B19 parvovirus during pregnancy, 14 (38%) had adverse outcomes, including spontaneous abortions, intrauterine fetal death, and congenital anomalies. Women at high risk for exposure (school teachers) should have screening for immunoglobulin G parvovirus-specific antibodies; if these are absent, they should avoid close contact with schoolchildren. Pregnant women with evidence of recent infection should have a level II ultrasound. Because no vaccine is currently available, routine screening cannot be recommended.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845316

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  13 in total

1.  Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women.

Authors:  J A Jordan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Quebec's safe working conditions for a Safe Maternity Experience program: survey of consultant physicians and human parvovirus B19 in Montreal-Centre.

Authors:  A T Koutsavlis; J F Boivin; R Simard; M Rossignol
Journal:  Can J Public Health       Date:  2000 Jul-Aug

3.  Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women.

Authors:  Allyson R Butchko; Jeanne A Jordan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 4.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

5.  Parvovirus B19 during pregnancy: a review.

Authors:  Elsa Giorgio; Maria Antonietta De Oronzo; Irene Iozza; Angela Di Natale; Stefano Cianci; Giovanna Garofalo; Anna Maria Giacobbe; Salvatore Politi
Journal:  J Prenat Med       Date:  2010-10

Review 6.  Intrauterine transfusion with red cells and platelets.

Authors:  K J Moise
Journal:  West J Med       Date:  1993-09

7.  A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus.

Authors:  S Kajigaya; T Shimada; S Fujita; N S Young
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 8.  Erythema infectiosum and pregnancy-related complications.

Authors:  M Levy; S E Read
Journal:  CMAJ       Date:  1990-11-01       Impact factor: 8.262

9.  Prospective study of human parvovirus (B19) infection in pregnancy. Public Health Laboratory Service Working Party on Fifth Disease.

Authors: 
Journal:  BMJ       Date:  1990-05-05

Review 10.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.